Nami Surgical’s 2025 Round-Up: A Year of Progress and Momentum

Press Release

Nami Surgical’s 2025 Round-Up: A Year of Progress and Momentum

2025 has been a defining year for Nami Surgical, marked by significant technical progress, strategic growth, international engagement and continued investment in the team behind its technology.

Each milestone has built on the last, bringing Nami closer to its goal of delivering smaller, more precise ultrasonic tools for robotic-assisted surgery.

Advancing Nami’s technology

At the centre of Nami’s progress has been the continued development of its miniaturised ultrasonic scalpel platform.

Throughout 2025, the team reached several important technical milestones, including the development of a fully modular, smart ultrasonic driving system, designed to enable precise control of energy delivery at the surgical site.

Another significant milestone was preparation for Nami’s first cadaver study, representing an important step in evaluating the technology and progressing towards future in vivo testing.

The company also opened a purpose-built operating and mock clinical environment, expanding Nami’s ability to test and refine its technology in conditions designed to closely replicate the surgical environment.

Growing technical capability

Nami continued to expand its in-house capabilities throughout 2025, supported by close collaboration across engineering, operations and clinical teams.

Improvements to the company’s quality management system and expansion of its testing capabilities have contributed to significant advances in performance, including a 265% reduction in vessel-sealing times since April 2024.

These improvements demonstrate the importance of combining technical innovation with robust processes, effective communication and a strong focus on quality throughout the development process.

Investing in the team

Nami continued to grow its team during 2025, welcoming new expertise across engineering, operations, quality, clinical and advisory roles.

Specialists spanning regulatory and quality systems, CAD, transducers and mechanical engineering have strengthened the company’s capabilities as its technology and development programmes progress.

Nami has also continued to invest in emerging talent through internships, industry placements and university collaborations, providing opportunities for the next generation of engineers, scientists and MedTech professionals to gain experience within a growing medical technology company.

Strengthening leadership and expertise

Nami’s extended leadership and advisory network also grew during the year, bringing additional experience from MedTech entrepreneurs and intellectual property specialists with track records in developing and scaling innovative technologies internationally.

Their expertise is supporting Nami’s commercial strategy, development of its intellectual property portfolio and preparations for future international growth.

Recognition and industry engagement

2025 also brought important external recognition for Nami and its team.

Nami was named Business to Watch at the Women’s Enterprise Scotland Awards, recognising the company’s progress and the leadership of Co-founder and CTO Dr Rebecca Cleary.

Rebecca was also appointed to the Board of the Ultrasonic Industry Association, further strengthening Nami’s presence within the international ultrasonic community and creating new opportunities for collaboration across the sector.

Building international relationships

Throughout the year, the Nami team participated in conferences, industry events and trade missions across Europe, North America and Asia.

This included participation in the TMCi Innovate UK Global Incubator Programme in Texas, alongside scientific and surgical conferences and engagement with potential partners across international markets.

A Scottish HealthTech trade mission to Japan provided further insight into one of the world’s important surgical robotics markets, while creating new opportunities for conversations around collaboration and innovation.

Preparing for Nami’s next stage of growth

Another major milestone was the opening of Nami’s $10 million Series A funding round.

Building on the support of existing investors and growing interest in Nami’s technology, the Series A is intended to support continued R&D, international expansion and the development of new clinical applications as the company progresses towards commercial readiness.

Nami also continued to welcome partners, collaborators and other stakeholders into its facilities throughout the year. Showcase days, filming and behind-the-scenes insights have provided opportunities to share the people, processes and technology behind the company’s development.

Looking ahead

As surgical innovation continues to evolve, advances in areas including data-driven precision, artificial intelligence and new surgical techniques are creating new possibilities for clinicians and technology developers.

For Nami, the focus remains on adaptability, collaboration and patient-centred design.

2025 has been a year of meaningful progress and growing momentum. Looking ahead, Nami remains focused on developing technology that supports clinicians, improves patient outcomes and helps realise the potential of the next generation of robotic-assisted surgery.